Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce glycated hemoglobin levels via regulation of incretin function without secondary effects such as weight gain and hypoglycemia [4, 5]. Here, GLP1R is linked to Hypoglycemia.